Literature DB >> 31129709

Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis.

Lorenzo Gaetani1, Nicola Salvadori2, Viviana Lisetti2, Paolo Eusebi2, Andrea Mancini2, Lucia Gentili2, Angela Borrelli2, Emilio Portaccio3, Paola Sarchielli2, Kaj Blennow4,5, Henrik Zetterberg4,5,6,7, Lucilla Parnetti2, Paolo Calabresi2,8, Massimiliano Di Filippo2.   

Abstract

BACKGROUND: Cognitive impairment (CI) is a disabling symptom of multiple sclerosis (MS). Axonal damage disrupts neural circuits and may play a role in determining CI, but its detection and monitoring are not routinely performed. Cerebrospinal fluid (CSF) neurofilament light chain (NfL) is a promising marker of axonal damage in MS.
OBJECTIVE: To retrospectively examine the relationship between CSF NfL and CI in MS patients.
METHODS: CSF NfL concentration was measured in 28 consecutive newly diagnosed MS patients who underwent a neuropsychological evaluation with the Brief Repeatable Battery of Neuropsychological tests (BRBN).
RESULTS: CSF NfL was higher in patients with overall CI (947.8 ± 400.7 vs 518.4 ± 424.7 pg/mL, p < 0.01), and with impairment in information processing speed (IPS) (820.8 ± 413.6 vs 513.6 ± 461.4 pg/mL, p < 0.05) and verbal fluency (1292 ± 511 vs 582.8 ± 395.4 pg/mL, p < 0.05), and it positively correlated with the number of impaired BRBN tests (r = 0.48, p = 0.01) and cognitive domains (r = 0.47, p = 0.01). Multivariate analyses taking into account potential confounders confirmed these findings.
CONCLUSION: CSF NfL is higher in MS patients with CI and impaired IPS and verbal fluency. Large myelinated axons injury, causing neural disconnection, may be an important determinant of CI in MS and can be reliably measured through CSF NfL.

Entities:  

Keywords:  Cerebrospinal fluid; Cognitive impairment; Information processing speed; Multiple sclerosis; Neurofilament light chain; Verbal fluency

Mesh:

Substances:

Year:  2019        PMID: 31129709     DOI: 10.1007/s00415-019-09398-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

1.  Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis.

Authors:  Eleonora Virgilio; Domizia Vecchio; Ilaria Crespi; Chiara Puricelli; Paolo Barbero; Giulia Galli; Roberto Cantello; Umberto Dianzani; Cristoforo Comi
Journal:  J Neurol       Date:  2022-01-28       Impact factor: 4.849

Review 2.  Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis.

Authors:  Patrizia LoPresti
Journal:  Biomedicines       Date:  2022-05-06

3.  miR-150-5p and let-7b-5p in Blood Myeloid Extracellular Vesicles Track Cognitive Symptoms in Patients with Multiple Sclerosis.

Authors:  Federica Scaroni; Caterina Visconte; Maria Serpente; Maria Teresa Golia; Martina Gabrielli; Marijn Huiskamp; Hanneke E Hulst; Tiziana Carandini; Milena De Riz; Anna Pietroboni; Emanuela Rotondo; Elio Scarpini; Daniela Galimberti; Charlotte E Teunissen; Maureen van Dam; Brigit A de Jong; Chiara Fenoglio; Claudia Verderio
Journal:  Cells       Date:  2022-05-05       Impact factor: 7.666

4.  Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study.

Authors:  Marie Eckerström; Staffan Nilsson; Henrik Zetterberg; Kaj Blennow; Anna Grahn
Journal:  Sci Rep       Date:  2020-12-28       Impact factor: 4.379

5.  Neurofilament light: a possible prognostic biomarker for treatment of vascular contributions to cognitive impairment and dementia.

Authors:  Christina Hoyer-Kimura; John P Konhilas; Heidi M Mansour; Robin Polt; Kristian P Doyle; Dean Billheimer; Meredith Hay
Journal:  J Neuroinflammation       Date:  2021-10-15       Impact factor: 8.322

6.  Assessing the presence of oligoclonal IgM bands as a prognostic biomarker of cognitive decline in the early stages of multiple sclerosis.

Authors:  Clàudia Coll-Martinez; Ester Quintana; Judit Salavedra-Pont; Maria Buxó; Marina González-Del-Rio; Immaculada Gómez; María Muñoz-San Martín; Luisa María Villar; Gary Álvarez-Bravo; René Robles-Cedeño; Lluís Ramió-Torrentà; Jordi Gich
Journal:  Brain Behav       Date:  2021-11-18       Impact factor: 2.708

7.  CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease.

Authors:  Linda P Oosterveld; Tessa I Kuiper; Nour K Majbour; Inge M W Verberk; Karin D van Dijk; Jos W R Twisk; Omar M El-Agnaf; Charlotte E Teunissen; Henry C Weinstein; Martin Klein; Henk W Berendse; Wilma D J van de Berg
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

8.  Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers.

Authors:  Lorenzo Gaetani; Nicola Salvadori; Elena Chipi; Lucia Gentili; Angela Borrelli; Lucilla Parnetti; Massimiliano Di Filippo
Journal:  Neural Regen Res       Date:  2021-01       Impact factor: 5.135

Review 9.  Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.

Authors:  Tamás Biernacki; Zsófia Kokas; Dániel Sandi; Judit Füvesi; Zsanett Fricska-Nagy; Péter Faragó; Tamás Zsigmond Kincses; Péter Klivényi; Krisztina Bencsik; László Vécsei
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923

Review 10.  The potential of serum neurofilament as biomarker for multiple sclerosis.

Authors:  Stefan Bittner; Jiwon Oh; Eva Kubala Havrdová; Mar Tintoré; Frauke Zipp
Journal:  Brain       Date:  2021-11-29       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.